Drug
JNJ-42165279 clinical trials
Also written JNJ-42165279.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
- JNJ-42165279
- 5
Studies by the year they started
8 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Janssen Research & Development, LLC (7) · Janssen-Cilag International NV (1)
Studies
Open first, then newest update. How each study uses JNJ-42165279 is read from its arms, and is right about nine times in ten.
Testing it · 8
- An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious DistressCompletedPhase 2Janssen Research & Development, LLCNCT02498392Written as JNJ-42165279
- A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety DisorderCompletedPhase 2Janssen Research & Development, LLCNCT02432703Written as JNJ-42165279
- A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT03564379Written as JNJ-42165279
- A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum DisorderCompletedPhase 2Janssen Research & Development, LLCNCT03664232Written as JNJ-42165279
- A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male ParticipantsCompletedPhase 1Janssen-Cilag International NVNCT01650597Written as JNJ-42165279 2.5 - 500 mg oral
- A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279CompletedPhase 1Janssen Research & Development, LLCNCT02169973Written as JNJ-42165279
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT01964651Written as JNJ-42165279 50 mg
- The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male VolunteersCompletedPhase 1Janssen Research & Development, LLCNCT01826786Written as JNJ-42165279 (100 mg)
Given in every arm · 1 — JNJ-42165279 is usual care beside what is tested
Codes
What other systems call JNJ-42165279 · ClinicalTrials.gg INT001126
- MeSH (NLM) C000632387JNJ-42165279One source ClinicalTrials.gov
- Wikidata Q25101230JNJ-42165279One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632387 | JNJ-42165279 | One source ClinicalTrials.gov |
| Wikidata | Q25101230 | JNJ-42165279 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.